New drug cocktail shows promise for Hard-to-Treat breast cancer
NCT ID NCT05583110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of three drugs—tucatinib, trastuzumab, and vinorelbine—in 13 people with HER2-positive breast cancer that had spread or could not be surgically removed. The goal was to see how many patients' tumors shrank or disappeared. The trial was terminated early, so the full results are not available, but early data may help guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tucatinib (Tukysa) combined with trastuzumab and vinorelbine
What this could lead to
If successful, this combination could offer a new treatment option for people with HER2-positive breast cancer that has spread or cannot be removed by surgery.
What could go wrong
This was a small, early-phase trial that ended early, so results are limited. The combination may not work better than existing treatments and could cause side effects like diarrhea or low blood cell counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo hospitalario Universitario Insular-Materno Infantil
Las Palmas de Gran Canaria, Las Palmas, 35016, Spain
-
Hospital Clínico Universitario Lozano Blesa
Zaragoza, Aragon, 50009, Spain
-
Hospital Clínico Universitario de Valladolid
Valladolid, Castille and León, 47003, Spain
-
Hospital Costa del Sol
Málaga, Andalusia, 29603, Spain
-
Hospital General Universitario Gregorio Marañón
Madrid, 28009, Spain
-
Hospital Nuestra Señora de Sonsoles
Ávila, Castille and León, 05004, Spain
-
Hospital San Juan de Alicante
Alicante, Valencia, 03550, Spain
-
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, 33011, Spain
-
Hospital Universitario Donostia
Donostia / San Sebastian, Basque Country, 20014, Spain
-
Hospital Universitario Quironsalud Madrid
Madrid, 28223, Spain
-
Hospital Universitario Reina Sofía
Córdoba, Andalusia, 14004, Spain
-
Hospital Universitario Virgen de Valme
Seville, Andalusia, 41014, Spain
-
Hospital Universitario de Araba
Vitoria-Gasteiz, Álava, 01009, Spain
-
Hospital Universitario de Bádajoz
Bádajoz, Extremadura, 06080, Spain
-
Hospital Universitario de Jaén
Jaén, Andalusia, 23007, Spain
-
Hospital Universitario de Jeréz De La Frontera
Cadiz, Andalusia, 11407, Spain
-
Hospital Álvaro Cunqueiro
Vigo, Galicia, 36213, Spain
-
ICO Badalona
Barcelona, Catalonia, 08916, Spain